Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Social Anxiety Disorder
Interventions: Ziprasidone, Sertraline; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Schizophrenia
Interventions: AVE1625, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Bipolar Disorder
Interventions: risperidone, aripiprazole; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 7 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: SEP-363856; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 5 more

Conditions: Bipolar Disorder
Interventions: Aspirin, N-acetyl-cysteine (NAC), Sugar Pill; Drug · Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Antipsychotics, Pregnancy
Interventions: Antipsychotics, Non-antipsychotic medication, No Medication; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Olanzapine, Risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 16 Years to 40 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 2
States / cities: Glen Oaks, New York • The Bronx, New York

Conditions: Secondary Parkinsonism, Parkinson's Disease
Interventions: no intervention; Other
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine (Zyprexa), Typicals; Drug
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Interventions: Varenicline; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Early Psychosis
Interventions: Decision aid; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Linagliptin; Drug
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Neuroleptic-Induced Tremor
Interventions: Gabapentin; Drug
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions: Clozapine versus typical (conventional) and atypical antipsychotic medications; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 19 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Jamaica Plain, Massachusetts

Conditions: Hyperglycemia, Hyperlipidemia
Interventions: Olanzapine, Ziprasidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Safety and Tolerability of Iloperidone
Interventions: iloperidone (oral tablet); Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • North Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
Interventions: Blood Draw; Other
Lead sponsor: Creighton University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Metabolic Complications
Interventions: Metformin, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: RO4917838, Placebo, Standard antipsychotic therapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Granada Hills, California • Los Angeles, California • Oceanside, California + 10 more

Conditions: Weight Gain
Interventions: Olanzapine plus modafinil, Olanzapine plus placebo; Drug
Lead sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Bipolar Disorder
Interventions: Seroquel®, quetiapine fumarate (atypical antipsychotic), lithium (mood stabilizer), divalproex (mood stabilizer); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 81
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 78 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia
Interventions: SPD489; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc); Drug
Lead sponsor: Matt Byerly; Other
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Geodon for the Treatment of Refractory Social Anxiety Disorder

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder

Maternal And Infant Antipsychotic Study

Treatment for First-Episode Schizophrenia

Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism

Zyprexa and Task Engagement in Schizophrenia

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Gabapentin for the Treatment of Neuroleptic-Induced Tremor

Alcoholism and Schizophrenia: Effects of Clozapine

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain

Metformin for the Prevention of the Metabolic Side-effects of Zyprexa

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

Effects of Modafinil on Olanzapine Weight Gain

Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia